Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...
Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...
A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...
Hosted on MSN
Engineered CAR-NK cells could evade immune rejection and target cancer more effectively
One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be ...
Natural killer (NK) cells are pivotal in the innate immune response against cancer and viral infections, with their presence in tumors correlating to better patient outcomes in various cancers.
Natural killer (NK) cells are pivotal in the innate immune response against cancer and viral infections, with their presence in tumors correlating to better patient outcomes in various cancers.
Allogeneic CD19 chimeric antigen receptor-natural killer (CAR-NK) cell therapy showed promise in patients with relapsed or refractory systemic lupus erythematosus (SLE), with sustained efficacy. The ...
(NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ...
French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). The company’s tetraspecific antibody controlled tumors and improved survival in mice and ...
ANKL is a rare and aggressive type of blood cancer affecting a type of white blood cell called natural killer (NK) cells. In ANKL, the NK cells are abnormal and multiply out of control, crowding out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results